Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of PCLX-001 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies

NCT04836195 is registered in ClinicalTrials.gov with Pacylex Pharmaceuticals as lead sponsor.

NCT NCT04836195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04836195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of PCLX-001 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies
Lead sponsor
Pacylex Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
September 14, 2021
Completion date
October 28, 2024
Enrollment
29 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, b-cell non hodgkin lymphoma